Serum YKL-40 Levels and White Matter Hyperintensities in Patients with Acute Ischemic Stroke

References

• Ma Q, Li R, Wang L., et al. Temporal trend and attributable risk factors of stroke burden in China, 1990-2019: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2021;6(12):e897–e906. doi:10.1016/s2468-2667(21)00228-0
   PubMed Web of Science ®Google Scholar
• Han F, Zhai FF, Wang Q, et al. Prevalence and risk factors of cerebral small vessel disease in a Chinese population-based sample. J Stroke. 2018;20(2):239–246. doi:10.5853/jos.2017.02110
   PubMed Web of Science ®Google Scholar
• Derraz I, Abdelrady M, Ahmed R, et al. Impact of white matter hyperintensity burden on outcome in large-vessel occlusion stroke. Radiology. 2022;304(1):145–152. doi:10.1148/radiol.210419
   Web of Science ®Google Scholar
• Ryu WS, Schellingerhout D, Hong KS, et al. White matter hyperintensity load on stroke recurrence and mortality at 1 year after ischemic stroke. Neurology. 2019;93(6):e578–e589. doi:10.1212/wnl.0000000000007896
   Web of Science ®Google Scholar
• Rist PM, Buring JE, Rexrode KM, Cook NR, Rost NS. Prospectively collected lifestyle and health information as risk factors for white matter hyperintensity volume in stroke patients. Eur J Epidemiol. 2019;34(10):957–965. doi:10.1007/s10654-019-00546-x
   Web of Science ®Google Scholar
• Lambertsen KL, Finsen B, Clausen BH. Post-stroke inflammation-target or tool for therapy? Acta Neuropathol. 2018;137(5):693–714. doi:10.1007/s00401-018-1930-z
   Web of Science ®Google Scholar
• Evans LE, Taylor JL, Smith CJ, Pritchard HAT, Greenstein AS, Allan SM. Cardiovascular comorbidities, inflammation, and cerebral small vessel disease. Cardiovasc Res. 2021;117(13):2575–2588. doi:10.1093/cvr/cvab284
   PubMed Web of Science ®Google Scholar
• Shoamanesh A, Preis SR, Beiser AS, et al. Inflammatory biomarkers, cerebral microbleeds, and small vessel disease: Framingham Heart Study. Neurology. 2015;84(8):825–832. doi:10.1212/wnl.0000000000001279
   PubMed Web of Science ®Google Scholar
• Zhang DD, Cao Y, Mu JY, et al. Inflammatory biomarkers and cerebral small vessel disease: a community-based cohort study. Stroke Vasc Neurol. 2022;7(4):302–309. doi:10.1136/svn-2021-001102
   Google Scholar
• Yeo I, Lee C, Han S, Yun J, Hong J. Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases. Pharmacol Ther. 2019;203:107394. doi:10.1016/j.pharmthera.2019.107394
   PubMed Web of Science ®Google Scholar
• Zhao T, Su Z, Li Y, Zhang X, You Q. Chitinase-3 like-protein-1 function and its role in diseases. Signal Transduct Target Ther. 2020;5(1):201. doi:10.1038/s41392-020-00303-7
   PubMed Web of Science ®Google Scholar
• Wang Y, Li B, Jiang Y, et al. YKL-40 Is associated with ultrasound-determined carotid atherosclerotic plaque instability. Front Neurol. 2021;12:622869. doi:10.3389/fneur.2021.622869
   Web of Science ®Google Scholar
• Pala S, Sari M, Kahveci G, Alizade E, Arslantas U, Uslu A. Plasma YKL-40 elevation on admission and follow-up is associated with diastolic dysfunction and mortality in patients with acute myocardial infarction. Cardiol Res Pract. 2018;2018:8701851. doi:10.1155/2018/8701851
   PubMed Web of Science ®Google Scholar
• Park H, Jun C, Jeon S, et al. Serum YKL-40 levels correlate with infarct volume, stroke severity, and functional outcome in acute ischemic stroke patients. PLoS One. 2012;7(12):e51722. doi:10.1371/journal.pone.0051722
   PubMed Web of Science ®Google Scholar
• Baldacci F, Lista S, Palermo G, Giorgi FS, Vergallo A, Hampel H. The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. Expert Rev Proteomics. 2019;16(7):593–600. doi:10.1080/14789450.2019.1628643
   PubMed Web of Science ®Google Scholar
• Dichev V, Kazakova M, Sarafian V. YKL-40 and neuron-specific enolase in neurodegeneration and neuroinflammation. Rev Neurosci. 2020;31(5):539–553. doi:10.1515/revneuro-2019-0100
   Web of Science ®Google Scholar
• Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35–41. doi:10.1161/01.str.24.1.35
   PubMed Web of Science ®Google Scholar
• Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351–356. doi:10.2214/ajr.149.2.351
   PubMed Web of Science ®Google Scholar
• Fazekas F, Niederkorn K, Schmidt R, et al. White matter signal abnormalities in normal individuals: correlation with carotid ultrasonography, cerebral blood flow measurements, and cerebrovascular risk factors. Stroke. 1988;19(10):1285–1288. doi:10.1161/01.str.19.10.1285
   PubMed Web of Science ®Google Scholar
• Gong X, Shan W, Yuan K, et al. Dietary Inflammatory Index and Leukoaraiosis in Patients with Ischemic Stroke. J Nutr Health Aging. 2020;24(5):473–477. doi:10.1007/s12603-020-1351-2
   Web of Science ®Google Scholar
• Yu F, Feng X, Li X, et al. Gut-Derived Metabolite Phenylacetylglutamine and White Matter Hyperintensities in Patients With Acute Ischemic Stroke. Front Aging Neurosci. 2021;13:675158. doi:10.3389/fnagi.2021.675158
   Web of Science ®Google Scholar
• Zong L, Yao M, Ni J, et al. Kidney function is associated with severity of white matter hyperintensity in patients with acute ischemic stroke/TIA. BMC Neurol. 2016;16(1):193. doi:10.1186/s12883-016-0714-0
   Google Scholar
• De Leeuw FE, de Groot JC, Achten E, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry. 2001;70(1):9–14. doi:10.1136/jnnp.70.1.9
   PubMed Web of Science ®Google Scholar
• Li T, Huang Y, Cai W, et al. Age-related cerebral small vessel disease and inflammaging. Cell Death Dis. 2020;11(10):932. doi:10.1038/s41419-020-03137-x
   PubMed Web of Science ®Google Scholar
• Giese AK, Schirmer MD, Dalca AV, et al. White matter hyperintensity burden in acute stroke patients differs by ischemic stroke subtype. Neurology. 2020;95(1):e79–e88. doi:10.1212/wnl.0000000000009728
   Web of Science ®Google Scholar
• Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol. 2013;12(5):483–497. doi:10.1016/s1474-4422(13)
   PubMed Web of Science ®Google Scholar
• Wu X, Ya J, Zhou D, Ding Y, Ji X, Meng R. Pathogeneses and Imaging Features of Cerebral White Matter Lesions of Vascular Origins. Aging Dis. 2021;12(8):2031–2051. doi:10.14336/ad.2021.0414
   Web of Science ®Google Scholar
• Low A, Mak E, Rowe JB, Markus HS, O’Brien JT. Inflammation and cerebral small vessel disease: a systematic review. Ageing Res Rev. 2019;53:100916. doi:10.1016/j.arr.2019.100916
   PubMed Web of Science ®Google Scholar
• Gao Y, Li D, Lin J, et al. Cerebral small vessel disease: pathological mechanisms and potential therapeutic targets. Front Aging Neurosci. 2022;14:961661. doi:10.3389/fnagi.2022.961661
   PubMed Web of Science ®Google Scholar
• Yuan J, Chen L, Wang J, et al. Adenosine A2A Receptor Suppressed Astrocyte-Mediated Inflammation Through the Inhibition of STAT3/YKL-40 Axis in Mice With Chronic Cerebral Hypoperfusion-induced White Matter Lesions. Front Immunol. 2022;13:841290. doi:10.3389/fimmu.2022.841290
   Web of Science ®Google Scholar
• Huss A, Abdelhak A, Mayer B, et al. Association of Serum GFAP with Functional and Neurocognitive Outcome in Sporadic Small Vessel Disease. Biomedicines. 2022;10(8):1869. doi:10.3390/biomedicines10081869
   Web of Science ®Google Scholar
• Kjaergaard AD, Bojesen SE, Nordestgaard BG, Johansen JS. YKL-40 and alcoholic liver and pancreas damage and disease in 86,258 individuals from the general population: cohort and Mendelian randomization studies. Clin Chem. 2014;60(11):1429–1440. doi:10.1373/clinchem.2014.229096
   PubMed Web of Science ®Google Scholar
• Shi G, Chen W, Gong P, et al. The Relationship Between Serum YKL-40 Levels on Admission and Stroke-Associated Pneumonia in Patients with Acute Ischemic Stroke. J Inflamm Res. 2021;14:4361–4369. doi:10.2147/JIR.S329612
   PubMed Web of Science ®Google Scholar
• Libreros S, Garcia-Areas R, Shibata Y, Carrio R, Torroella-Kouri M, Iragavarapu-Charyulu V. Induction of proinflammatory mediators by CHI3L1 is reduced by chitin treatment: decreased tumor metastasis in a breast cancer model. Int J Cancer. 2012;131(2):377–386. doi:10.1002/ijc.26379
   PubMed Web of Science ®Google Scholar
• Qin W, Li J, Zhu R, et al. Melatonin protects blood-brain barrier integrity and permeability by inhibiting matrix metalloproteinase-9 via the NOTCH3/NF-κB pathway. Aging. 2019;11(23):11391–11415. doi:10.18632/aging.102537
   PubMedGoogle Scholar
• Zozulya A, Weidenfeller C, Galla HJ. Pericyte-endothelial cell interaction increases MMP-9 secretion at the blood-brain barrier in vitro. Brain Res. 2008;1189:1–11. doi:10.1016/j.brainres.2007.10.099
   PubMed Web of Science ®Google Scholar
• Yasuda T, Kaneto H, Katakami N, et al. YKL-40, a new biomarker of endothelial dysfunction, is independently associated with albuminuria in type 2 diabetic patients. Diabetes Res Clin Pract. 2011;91(2):e50–2. doi:10.1016/j.diabres.2010.11.015
   PubMed Web of Science ®Google Scholar
• Bui TM, Wiesolek HL, Sumagin R. ICAM-1: a master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis. J Leukoc Biol. 2020;108(3):787–799. doi:10.1002/jlb.2mr0220-549r
   PubMed Web of Science ®Google Scholar
• Simka M. Blood brain barrier compromise with endothelial inflammation may lead to autoimmune loss of myelin during multiple sclerosis. Curr Neurovasc Res. 2009;6(2):132–139. doi:10.2174/156720209788185605
   Web of Science ®Google Scholar
• Chen Y, Xu J, Pan Y, et al. Association of Trimethylamine N-Oxide and Its Precursor With Cerebral Small Vessel Imaging Markers. Front Neurol. 2021;12:648702. doi:10.3389/fneur.2021.648702
   Web of Science ®Google Scholar
• Simpson JE, Ince PG, Higham CE, et al. Microglial activation in white matter lesions and nonlesional white matter of ageing brains. Neuropathol Appl Neurobiol. 2007;33(6):670–683. doi:10.1111/j.1365-2990.2007.00890.x
   PubMed Web of Science ®Google Scholar
• Fadul MM, Heath PR, Cooper-Knock J, et al. Transcriptomic Analysis of Age-Associated Periventricular Lesions Reveals Dysregulation of the Immune Response. Int J Mol Sci. 2020;21(21):7924. doi:10.3390/ijms21217924
   Web of Science ®Google Scholar
• Fazekas F, Kleinert R, Offenbacher H, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993;43(9):1683–1689. doi:10.1212/wnl.43.9.1683
   PubMed Web of Science ®Google Scholar
• Fernando MS, Simpson JE, Matthews F, et al. White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. Stroke. 2006;37(6):1391–1398. doi:10.1161/01.Str.0000221308.94473.14
   PubMed Web of Science ®Google Scholar